SCHEMBL2298285

SCHEMBL2298285

Fc1ccc([C@H]2CNCCO2)cc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1637335 1.00
Hydrochloric Acid SCHEMBL4071771 0.98
Hydrochloric Acid SCHEMBL82651 0.98
Oxalic Acid SCHEMBL12521042 0.91
SCHEMBL15111546 0.85
SCHEMBL15121099 0.85
SCHEMBL15111548 0.85
Hydrochloric Acid SCHEMBL15111543 0.84
Hydrochloric Acid SCHEMBL15111553 0.84
Hydrochloric Acid SCHEMBL15111541 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1147254-A Prodrugs of morpholine tachykinin receptor antagonists MERCK & CO INC (US) 1997-04-09 CN claimed
CN-104650143-B The method for preparing fosaprepitant dimeglumine intermediate 山东新时代药业有限公司 2018-10-02 CN disclosed
CN-102675369-B One kind prepares [3 [(2R) [(1R) 1 [3,5 two (trifluoromethyl) phenyl] ethyoxyl] 3 (S) (4 fluorophenyl) morpholines 4 base] methyl] 5 oxos 4,5 dihydros [1,2,4] base of triazole 1] benzyl ester of phosphonic acids one new method 北京华众思康医药技术有限公司 2017-07-11 CN disclosed
EP-2809661-B1 NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS LILLY CO ELI (US) 2016-04-06 EP disclosed
US-8993568-B2 Morpholinyl derivatives useful as MOGAT-2 inhibitors ELI LILLY AND COMPANY (US) 2015-03-31 US disclosed
US-8940738-B2 Pyrimidone compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-01-27 US disclosed
US-8940738-B2 Pyrimidone compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-01-27 US disclosed
US-20150005305-A1 NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS ELI LILLY AND COMPANY (US) 2015-01-01 US disclosed
CN-102675369-A New method for preparing fosaprepitant intermediate BEIJING HUAZHONGSIKANG PHARMACEUTICAL TECHNOLOGY CO LTD 2012-09-19 CN disclosed
EP-2097409-B1 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2012-09-12 EP disclosed
EP-1558252-A2 SUBSTITUTED FURO 2,3-B] PYRIDINE DERIVATIVES Merck & Co., Inc. (US) 2005-08-03 EP disclosed
WO-2004012671-A2 SUBSTITUTED FURO [2,3-B] PYRIDINE DERIVATIVES MERCK & CO., INC. (US) 2004-02-12 WO disclosed
CN-1131864-C Chemical synthesis method of morpholine derivative MERCK SHARP & DOHME LTD. (GB) 2003-12-24 CN disclosed
CN-1075812-C Prodrugs of morpholine tachykinin receptor antagonists MERCK & CO INC (US) 2001-12-05 CN disclosed
CN-1067683-C Substituted morpholine derivatives and their use as therapeutic agents MERK SHARP & DOHME LTD (GB) 2001-06-27 CN disclosed
EP-0778831-A1 MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP &amp; DOHME LTD. (GB) 1997-06-18 EP disclosed
CN-1147254-A Prodrugs of morpholine tachykinin receptor antagonists MERCK & CO INC (US) 1997-04-09 CN disclosed
CN-1139927-A Substituted morpholine derivatives and their use as therapeutic agents MERK SHARP & DOHME LTD (GB) 1997-01-08 CN disclosed
EP-0748320-A1 PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1996-12-18 EP disclosed
WO-1996007649-A1 MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 1996-03-14 WO disclosed